The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.
Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health